Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Bristol-Myers Squibb will pay Repare Therapeutics $65 million and invest $15 million in the start-up as part of a cancer drug–discovery deal. Some common mutations in cancer cells impair their ability to fix damaged DNA, forcing the cells to rely on alternative DNA repair mechanisms as a crutch. Repare uses CRISPR-Cas9 gene-editing screens to knock out genes, pinpoint the proteins responsible for the crutch, and design small-molecule drugs to target them. The strategy is called synthetic lethality. Repare could earn up to $3 billion in milestone payments from BMS.
This article has been sent to the following recipient: